目的 检测乳腺浸润性导管癌拓扑异构酶Ⅱα(TOP 2 A)基因状态变化,探讨其异常率与人类表皮生长因子受体2(HER2)、雌激素受体(ER)、孕激素受体(PR)、Ki67蛋白表达及临床病理特征之间的相关性.方法 筛选乳腺浸润性导管癌患者371例,通过FISH检测TOP2A基因异常情况,分析TOP2A基因状态与ER、PR、Ki67、HER2蛋白表达及临床病理特征的关系.结果 371例乳腺浸润性导管癌患者中TOP 2A基因异常率20.49%(76/371),其中基因扩增64例(17.25%),基因缺失12例(3.24%),TOP 2A基因异常与ER、PR蛋白表达无相关(P>0.05),TOP 2A基因扩增随着Ki67与HER2蛋白表达的增强而增高(P<0.05),TOP 2A基因异常与年龄、性别、部位及腋窝淋巴结转移差异无相关(P >0.05),与肿瘤大小相关(P <0.05).结论 TOP2A基因及其相关基因蛋白的检测为乳腺浸润性导管癌蒽环类药物的使用提供了参考性依据.
Objective To investigate the correlation between topoisomerase Ⅱα ( TOP2A) gene and breast invasive ductal carcinoma. Methods Totally 371 patients with breast invasive ductal carcinoma were included in this study.Abnormalities of TOP2A gene was determined.Expression of ER,PR,Ki67 and HER2 were measured. Clinical characteristics of patients were recorded. Results The abnormal rate of TOP2A gene was 20.49%(76/371), among which were gene amplification (64, 17.25%), gene deletion (12, 3.24%). No obvious relationship was observed between abnormality of TOP2A and age,gender,site,axillary lymph node metastasis orexpression of ER and PR (P>0.05).Abnormality of TOP2A was positively associated with tumor size and enhance dexpression of Ki67 and HER2(P<0.05). Conclusions Abnormality of TOP2A gene provides fundamental evidence for anthracycline as therapeutic approach for patients with breast invasive ductal carcinoma.
评论